Bone morphogenetic protein signaling and growth suppression in colon cancer
- 1 July 2006
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Gastrointestinal and Liver Physiology
- Vol. 291 (1) , G135-G145
- https://doi.org/10.1152/ajpgi.00482.2005
Abstract
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β superfamily, which utilize BMP receptors and intracellular SMADs to transduce their signals to regulate cell differentiation, proliferation, and apoptosis. Because mutations in BMP receptor type IA (BMPRIA) and SMAD4 are found in the germline of patients with the colon cancer predisposition syndrome juvenile polyposis, and because the contribution of BMP in colon cancers is largely unknown, we examined colon cancer cells and tissues for evidence of BMP signaling and determined its growth effects. We determined the presence and functionality of BMPR1A by examining BMP-induced phosphorylation and nuclear translocation of SMAD1; transcriptional activity via a BMP-specific luciferase reporter; and growth characteristics by cell cycle analysis, cell growth, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide metabolic assays. These assays were also performed after transfection with a dominant negative (DN) BMPR1A construct. In SMAD4-null SW480 cells, we examined BMP effects on cellular wound assays as well as BMP-induced transcription in the presence of transfected SMAD4. We also determined the expression of BMPR1A, BMP ligands, and phospho-SMAD1 in primary human colon cancer specimens. We found intact BMP signaling and modest growth suppression in HCT116 and two derivative cell lines and, surprisingly, growth suppression in SMAD4-null SW480 cells. BMP-induced SMAD signaling and BMPR1A-mediated growth suppression were reversed with DN BMPR1A transfection. BMP2 slowed wound closure, and transfection of SMAD4 into SW480 cells did not change BMP-specific transcriptional activity over controls due to receptor stimulation by endogenously produced ligand. We found no cell cycle alterations with BMP treatment in the HCT116 and derivative cell lines, but there was an increased G1 fraction in SW480 cells that was not due to increased p21 transcription. In human colon cancer specimens, BMP2 and BMP7 ligands, BMPRIA, and phospho-SMAD1 were expressed. In conclusion, BMP signaling is intact and growth suppressive in human colon cancer cells. In addition to SMADs, BMP may utilize SMAD4-independent pathways for growth suppression in colon cancers.Keywords
This publication has 39 references indexed in Scilit:
- Diet, Lifestyle, and Genomic Instability in the North Carolina Colon Cancer StudyCancer Epidemiology, Biomarkers & Prevention, 2005
- The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutationsJournal of Medical Genetics, 2004
- BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cellsBiochemical and Biophysical Research Communications, 2004
- De Novo Crypt Formation and Juvenile Polyposis on BMP Inhibition in Mouse IntestineScience, 2004
- Bone morphogenetic protein signaling in prostate cancer cell linesJournal of Cellular Biochemistry, 2003
- Germline Mutations in BMPR1A/ALK3 Cause a Subset of Cases of Juvenile Polyposis Syndrome and of Cowden and Bannayan-Riley-Ruvalcaba Syndromes*American Journal of Human Genetics, 2001
- Specific Activation of Smad1 Signaling Pathways by the BMP7 Type I Receptor, ALK2Journal of Biological Chemistry, 1998
- Mutations in the SMAD4/DPC4 Gene in Juvenile PolyposisScience, 1998
- DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1Science, 1996
- Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.The Journal of cell biology, 1995